FDA Approves Cabozantinib for Previously Treated Advanced Neuroendocrine Tumors
MONDAY, March 31, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine ...
